Alnylam’s vutrisiran aces ATTR cardiomyopathy readout

cafead

Administrator
Staff member
  • cafead   Jun 24, 2024 at 10:52: AM
via Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up regulatory filings.

article source
 

<